Please select the option that best describes you:
For a patient with IIIC1 (micromets), MSI-high, Grade 2 endometrial adenocarcinoma who has undergone full surgical staging, do you recommend adding immunotherapy to adjuvant chemotherapy + radiation?
Answer from: Radiation Oncologist at Academic Institution
No.RUBY only allowed stage IIIC2, any histology, or stage IIIC1 high-risk histology (carcinosarcoma/serous/clear cell) fully resected patients to be enrolled.NRG-GY018 did not allow any fully resected stage III patient to be included. All stage III patients needed to have unresected gross disease.
Comments
at BayCare Medical Group
The crux of the issue is the same question I asked...
The crux of the issue is the same question I asked...
at H. Lee Moffitt Cancer Center and Research Institute
Dr. @Logan Corey, thanks for the shout-out on that...
Dr. @Logan Corey, thanks for the shout-out on that...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
@Logan Corey, happy to discuss and help each side ...
@Logan Corey, happy to discuss and help each side ...
Go to page:
Answer from: Radiation Oncologist at Academic Institution
KEYNOTE-B21 has been published which now supports the use of immunotherapy in fully resected stage III patients that are dMMR, relevant to this clinical scenario, based on a PFS benefit.Van Gorp et al., PMID 39284383Slomovitz et al., PMID 39411812
Comments
Radiation Oncologist at Legacy Health System
It is interesting to note that the authors did not...
It is interesting to note that the authors did not...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
Good catch on DFS vs PFS - I use them interchangea...
Good catch on DFS vs PFS - I use them interchangea...
Very nice summary of data to help guide all of us....
Great up to date summary